Kopran Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹118Cr
- −22.2% YoY
- −12.8% QoQ
- Net profit
- −₹10Cr
- Q2 FY25: ₹7 Cr
- Margin
- −4.48%
- −14.2 pp YoY
- −14.9 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Kopran Ltd Q2 FY26 key numbers
- Revenue
- Revenue from Operations for Q2 FY 2025-26: Rs. 11,791 lakhs.
As stated in Kopran Ltd's Q2 FY26 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Kopran Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue from Operations for Q2 FY 2025-26: Rs. 11,791 lakhs. Quarter (Q2 FY 2025-26) Financials (Page 5):.
From Kopran Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Revenue from Operations for Q2 FY 2025-26: Rs. 11,791 lakhs
- Revenue from Operations for Q2 FY 2024-25: Rs. 15,156 lakhs
- Year-on-year change: Decline of Rs. 3,365 lakhs (~22.2% decrease)
- Sales/Other Income (HY figures):
- HY FY 2025-26: Rs. 25,331 lakhs
- HY FY 2024-25: Rs. 63,359 lakhs
- Formulations Segment Revenue (Q2 FY 2025-26): Rs. 4,017 lakhs
- Formulations Segment Revenue (HY FY 2025-26): Rs. 9,095 lakhs
2 more points from Kopran Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Kopran Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Kopran Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Kopran Ltd said on order book & pipeline — free account, 30 seconds.
Kopran Ltd — Quarterly revenue & net profit
Kopran Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 118 | 152 | -22.2% | 135 | -12.8% |
| Operating profit (EBITDA) | -5 | 15 | -135.8% | 14 | -137.4% |
| Operating margin | -4.48% | 9.72% | -14.2 pp | 10.45% | -14.9 pp |
| Profit before tax | -12 | 10 | -220.4% | 10 | -217.5% |
| Net profit (PAT) | -10 | 7 | -234.4% | 7 | -233.2% |
| EPS (₹) | -2.06 | 1.53 | -234.6% | 1.54 | -233.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹211 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Kopran's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Kopran Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Kopran Ltd Q2 FY26 results?
Revenue from Operations for Q2 FY 2025-26: Rs. 11,791 lakhs. Quarter (Q2 FY 2025-26) Financials (Page 5):.
What is Kopran Ltd share price analysis?
Kopran Ltd currently shows a neutral. The stock trades at a P/E of 53.7 with a market cap of ₹1,342 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
